DB-OTO, Gene Therapy Product Designed to Provide Hearing to Individuals with Otoferlin Mutations

Time: 1:45 pm
day: Post Conference Day


• DB-OTO is an AAV-based dual-vector investigational product candidate designed to restore hearing to individuals with profound, congenital hearing loss due to otoferlin deficiency
• DB-OTO utilizes a proprietary, cell-selective promoter to express otoferlin in hair cells
• Pre-clinical studies have demonstrated restoration of hearing in a mouse model after administration of DB-OTO